Kunle Odunsi, MD, PhD, FRCOG, FACOG

Roswell Park Cancer Institute
Chair, Department of Gynecologic Oncology
The M. Steven Piver Professor of Gynecologic Oncology
Executive Director, Center for Immunotherapy
Co-Leader, Tumor Immunology and Immunotherapy Program
School of Medicine and Biomedical Sciences State University of New York at Buffalo
Professor of Gynecology & Obstetrics
Cancer Research Institute/Ludwig Institute for Cancer Research
Director, US Cancer Vaccine Collaborative Program

Dr. Adekunle "Kunle" Odunsi is Chair of the Department of Gynecologic Oncology, Executive Director of the Center for Immunotherapy and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Cancer Institute. He joined RPCI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology, Department of Surgical Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He was admitted to the Royal College of Obstetricians and Gynecologists in 1991.

Dr. Odunsi completed a research fellowship in Molecular Oncology and earned his Ph.D. at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK. Subsequently, he completed residency training in Obstetrics & Gynecology at the Yale University School of Medicine, New Haven, CT, and clinical fellowship in Gynecologic Oncology at RPCI. He is a Fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom. He is also a Fellow of the American College of Obstetricians and Gynecologists.

Dr. Odunsi is licensed by New York State and certified in Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. He is also board certified in the sub-specialty of Gynecologic Oncology.

Dr. Odunsi’s research interests include the molecular characterization of tumor antigens in ovarian cancer and their application to the development of vaccine therapies for the disease. 

Dr. Odunsi has authored or co-authored more than 140 journal publications and  book chapters. He is Associate Editor for BMC Cancer. He also is an Ad Hoc Reviewer for the American Journal of Obstetrics and Gynecology, BLOOD, BMC Cancer, Cancer Immunity, Cancer Immunology Immunotherapy, Cancer Letters, Cancer Research, Clinical Cancer Research, Expert Opinion on Biological Therapy, Fertility and Sterility, Future Oncology, Gynecologic Oncology, International Journal of Cancer, Journal of Clinical Pathology, Journal of the Society for Gynecologic Investigation, The Lancet, Mayo Clinic Proceedings,  Molecular Cancer Therapeutics, Oncogene, Oncology PLoS ONE and the Proceedings of the National Academy of Sciences, U.S.A.

Areas of Expertise: 
Cervical cancer
Ovarian cancer
Trophoblastic disease
Uterine cancer
Vaginal cancer
Vulvar cancer
Special Interests: 
Molecular characterization of tumor antigens in ovarian cancer
Development of cancer vaccine therapies
Early detection of ovarian cancer
Board Certification: 
Obstetrics & Gynecology, American Board of Obstetrics & Gynecology
Gynecologic Oncology, American Board of Obstetrics & Gynecology
Fellowship: 
Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY
Residency: 
Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT
Education and Training: 
MD - University of Ife, College Of Health Sciences, Ile-Ife, Nigeria
MRCOG - The Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK
PhD - Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, Oxfordshire, UK